Liver Cirrhoses
Conditions
Brief summary
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF
Detailed description
The current study was aimed at assessing whether a treatment based on combination of rifaximin and simvastatin would be effective in patients with decompensated cirrhosis to prevent ACLF development Considering that statins have been scarcely investigated in patients with decompensated cirrhosis due to a concern of potential higher liver and muscle toxicity in this population, a first LIVERHOPE\_SAFETY clinical trial (unpublished) was undergone to assess safety and toxicity of statins with decompensated cirrhosis. As a preliminary result of the LIVERHOPE\_SAFETY clinical trial, it was concluded that the dose of Simvastatin 20mg per day plus Rifaximin is not associated to a higher risk of liver or muscle toxicity in patients with decompensated cirrhosis and simvastatin 20 mg was established for the LIVERHOPE\_EFFICACY study.
Interventions
DRUGSimvastatin
Simvastatin 20 mg/day for 12 months
DRUGRifaximin
Rifaximin 400/8 hours for 12 months
Placebo of Simvastatin once a day for 12 months
Placebo of Rifaximin/8 hours for 12 months
Sponsors
Judit Pich
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Neither the participants nor the researchers will know which group the participants has been allocated to
Intervention model description
Phase III, multicentre, double-blind placebo-controlled, randomized clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology * Child-Pugh patients or Child-Pugh C patients (up to 12 points) * Women of child-bearing potential must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence.
Exclusion criteria
* Patients on treatment with statins or rifaximin up to one month before study inclusion. * Patients with contraindications for statins or rifaximin therapy. * Known hypersensitivity to simvastatin or rifaximin (or rifamycin derivatives). * Patients with CK elevation of 50% or more above the upper limit of normal at study inclusion. * Patients on treatment with potent inhibitors of CYP3A4 enzyme * Patients on treatment with drugs with potential interactions with simvastatin * Patients with previous history of myopathy. * Patients with previous history of intestinal obstruction or those who are at increased risk of this complication. * Patients with ACLF according to the criteria published by Moreau et al. * Serum creatinine ≥2 mg/dL (176.8 μmol/L). * Serum bilirubin\>5 mg/dL (85.5 μmol/L). * 12\. INR ≥2.5 * Bacterial infection within 10 days before study inclusion. * Gastrointestinal bleeding within 10 days before study inclusion. * Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the New-Haven classification. * Patients with active hepatocellular carcinoma or history of hepatocellular carcinoma that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria. * Patients on antiviral therapy for HCV or those who have received it within the last 6 months. * Severe alcoholic hepatitis requiring corticosteroid therapy (Maddrey's Discriminant function ≥ 32 and/or ABIC score \> 6.7). * Patients with active alcohol consumption of more than 21 units per week. * HIV infection. * Patients with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD \>2, chronic kidney disease with serum creatinine \>2mg/dL or under renal replacement therapy. * Patients with current extra hepatic malignancies including solid tumours and hematologic disorders. * Pregnancy or breastfeeding. * Patients included in other clinical trials in the month before inclusion. * Patients with mental incapacity, language barrier, bad social support or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study. * Refusal to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of ACLF at the end of the study | Month 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline in plasma cytokine levels including, but not limited to, oxide form of albumin at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Time to transplant-free survival at months1, 3, 6, 9 and 12 | months 1, 3, 6, 9 and 12 | — |
| Severity of ACLF assessed by number and types of organ failures at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | months 1, 3, 6, 9 and 12 | — |
| Frequency of hospital admissions due to complications of cirrhosis assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months. | baseline and months 1, 3, 6, 9 and 12 | — |
| Number of participants developing a new onset episode of ascitis assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | — |
| Number of participants presenting worsening of ascitis assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | Worsening of ascitis will be defined as increased diuretic dosage or need for large-volume parecentesis in patients who had never been treated with this procedure |
| Percentage of participants developing episodes of renal function impairment assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | Renal function impairment will be defined by AKI criteria, following criteria of the EASL Clinical Practice Guidelines for the management of patients with decompensated cirrosis |
| Percentage of participants developing the first episode of bleeding by esophageal or gastric varices at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | — |
| Number of bleeding episodes by esophageal or gastric varices per patient assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | — |
| Number of participants developing a new onset episode of hepatic encephalopathy (HE) assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | — |
| Number of participants developing a new onset episode of bacterial infection assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, TNFα at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, IL-6, IL-8, IL-10 and IL-1β at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, IFN-ɣ at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, G-CSF at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, VCAM at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, VCAM and VEGF at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, ADMA and SDMA at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma biomarker FABP4 at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma biomarker sCD-163 at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma biomarker vWF at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in urine biomarker NGAL at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in urine biomarker MCP-1 at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in urine biomarker albumin at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma renin concentration at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma norepinephrine concentration at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in plasma copeptin concentration at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes from baseline in blood levels of bacterial DNA or bacterial products at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Changes in microbiome composition by analysis of microbial genes and signature at baseline, 3 months, 6 months and 12 months | baseline and months 3, 6 and 12 | The aim of this secondary endpoint is to identify phylogenetic and functional composition in the gut microbiota of patients at different stages of liver disease by analysis of microbial genes and signature. As treatment with rifaximin has been associated to changes in microbiota composition in patients with cirrhosis, we will analyze the changes in microbiota signature and composition in patients under treatment with simvastatin and rifaximin at 3 months, 6 months and 12 months |
| Changes from baseline in liver function evaluated by MELD (Model For End-Stage Liver Disease) score at 1 month, 3 months, 6 months, 9 months and 12 months | months 1, 3, 6, 9 and 12 | MELD score is a system developed to evaluate the severity of chronic liver disease, and it involves serum bilirubin, creatinine and international normalized ratio values |
| Changes from baseline in liver function evaluated by CLIF-AD (Chronic Liver Failure - Acute Decompensation) score at 1 month, 3 months, 6 months, 9 months and 12 months | months 1, 3, 6, 9 and 12 | CLIF-AD score is a system created to evaluate the prognosis of patients with decompensated cirrosis, and it involves age, white cell count, creatinine, international normalized ratio and sodium |
| Changes from baseline in liver function evaluated by Child Pugh Score at 1 month, 3 months, 6 months, 9 months and 12 months | months 1, 3, 6, 9 and 12 | Child Pugh is a score created to evaluate the prognosis of patients with cirrosis based on clinical and analytical values. It involves serum bilirubin, coagulation, albumin and the presence of clinical complications of cirrhosis, as hepatic encephalopathy and ascites |
| Change in quality of life assessed by CLDQ questionnaire (Chronic Liver Disease Questionnaire) at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | Evaluated by patient administration. CLDQ questionnaire contains 29 items divided into six domains: Fatigue which includes perceptions of decreased energy and sleepiness; Emotional Function which measures mood and insomnia; Worry assessing concerns regarding disease progression and family; Activity considering eating habits and movement of heavy objects; and finally, 2 symptom domains, Abdominal Symptoms and Systemic Symptoms. All items refer to the previous 2 weeks on a 7 point Likert scale, with 1 corresponding to the maximum frequency (all of the time) and 7 to the minimum (none of the time). Scores range from 1 (worst) to 7 (least severe), in which higher scores indicate a minimum frequency of symptoms and, consequently, a better quality of life |
| Change of frailty and functional status assessed by Liver Frailty Index questionnaire at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | Liver Frailty Index questionnaire is an objectively measure physical frailty (a term that we believe embodies these extrahepatic manifestations of cirrhosis) in patients with end-stage liver disease (ESLD) and quantify its impact on health-related outcomes. It's composed by (1) Gender (Male or Female); (2) Dominant hand grip strength (kg), the means of three measures; (3) Chair stands (sec), time that it takes a patient to stand up and sit down in a chair 5 times without using their arms; and (4) Balance (sec), seconds holding 3 position balance tested in 3 positions for 10 seconds each the positions are side by side, semi tandem and tandem. Liver Frailty Index is calculated as: (-0:330 \* gender-adjusted grip strength) + (-2:529 \* number of chair stands per second) + (-0:040 \* balance time) + 6. The questionnaire does not have a minimum value and a maximum value. |
| Change of minimal hepatic encephalopathy assessed by PHES questionnaire (Psychometric Hepatic Encephalopathy Score) at baseline, 1 month, 3 months, 6 months, 9 months and 12 months | baseline and months 1, 3, 6, 9 and 12 | The PHES is a questionnaire used in the diagnosis of minimal hepatic encephalopathy (MHE) and can be used to assess motor speed, motor accuracy, concentration, attention, visual perception, visual-spatial orientation, visual construction and memory, which are related to most of neuropsychological impairments in MHE. The PHES is composed of five tests, number connection test-A (NCT-A), number connection test-B (NCT-B), serial dotting test (SDT), line tracing test (LTT) and digit symbol test (DST). This questionnaire measures the time that the patient spends doing the five exercises. The questionnaire does not have a minimum value and a maximum value, but as the score increases there is a worsening of outcome. |
| Changes from baseline in stigmatization assessed by a specific questionnaire at 3 months, 6 months and 12 months | months 3, 6 and 9 | Evaluated by patient administration. This questionnaire quantifies the presence of stigma among patients with cirrhosis. The questionnaire gives a total of 19 stigma-related questions with answer choices based on a four point Likert scale (strongly agree, agree, disagree, and strongly disagree). The questions are divided in four categories 1) discrimination, 2) stereotypes, 3) social isolation and 4) shame. The questionnaire does not have a minimum value and a maximum value, because is only a descriptive questionnaire that values patient perception regarding the disease. |
| Change in appearance of muscle toxicity at baseline, 1 month, 3 months, 6 months, 9 months and 12 months as defined using a specific statin-associated myopathy questionnaire | baseline and months 1, 3, 6, 9 and 12 | Appearance of muscle toxicity at baseline, 1 month, 3 months, 6 months, 9 months and 12 months as defined using a specific statin-associated myopathy questionnaire. This questionnaire consists of four questions that patients can answer yes or no. The patients met the study definition for appearance of muscle toxicity if one of the three of the following occurred: 1) They reported new or increased muscle pain, cramps, or aching, unassociated with exercise; 2) Symptoms persisted for at least 2 weeks; 3) Symptoms resolved within 2 weeks of stopping the study drug; and 4) Symptoms reoccurred within 4 weeks of restarting the study medication. |
| Number of patients with genetic polymorphisms of statins membrane transporter OATPB1 in all patients included in the study | month 12 | — |
| Changes from baseline in transaminases at 1 month, 3 months, 6 months, 9 months ans 12 months | months 1, 3, 6, 9 and 12 | — |
| Changes from baseline in alkaline phosphatase at 1 month, 3 months, 6 months, 9 months ans 12 months | months 1, 3, 6, 9 and 12 | — |
| Changes from baseline in plasma cytokine levels including, but not limited to, HNA2 at 3 months, 6 months and 12 months | months 3, 6 and 12 | — |
| Proportion of patients and severity of treatment-related adverse events during the study period | month 12 | — |
| Annualized incidence of ACLF during the study period | month 12 | — |
| Time to overall at the end of the study | month 12 | — |
| Time to disease related survival at the end of the study | month 12 | — |
| Changes from baseline in creatine kinase at 1 month, 3 months, 6 months, 9 months ans 12 months | months 1, 3, 6, 9 and 12 | — |
Countries
Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Outcome results
None listed